Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor

Eli Lilly and Company
Posted on: 16 Nov 09
Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his SuccessorPR NewswireINDIANAPOLIS, November 13

INDIANAPOLIS, November 13 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Steven M. Paul,M.D., executive vice president, science and technology, and president, LillyResearch Laboratories, will retire from Lilly effective February 28, 2010.Lilly has also announced that Jan M. Lundberg, Ph.D., executive vicepresident and head of global discovery research, AstraZeneca, is to becomehis successor. Paul is committed to working closely with Lundberg to ensure asuccessful transition. Lundberg plans to join Lilly in Indianapolis as earlyas January 2010, subject to completion of the U.S. immigration process.

Paul joined Lilly as vice president, central nervous system discoveryresearch and decision-phase medical research, in 1993. He was named groupvice president, therapeutic area discovery research and clinicalinvestigation, in 1998. Paul has been in his current role since 2003. Beforecoming to Lilly, Paul was the scientific director of the National Instituteof Mental Health.

"Under Steve's leadership, we now have the most robust pipeline inLilly's history, including approximately 60 unique potential medicines-bothsmall molecules and biologics-in human testing. Additionally, Steve hashelped to recruit many of the top leaders we have in LRL today. Steve hasalso been actively involved in advancing Lilly's research in the area ofAlzheimer's disease, including solanezumab, one of Lilly's two late-stageAlzheimer's molecules," said John Lechleiter, Ph.D., Lilly chairman and chiefexecutive officer.

"Steve has also been instrumental in successfully transforming R&D overthe past several years, including the implementation of the FIPNet model,moving Lilly from a fully integrated pharmaceutical company, where wepreviously owned all aspects of the value chain, to a fully integratedpharmaceutical network, where we are playing bigger than our size. He hasalso been a tremendous ambassador for the company, representing Lilly throughhis involvement with biopharmaceutical industry, scientific, and medicalorganizations," added Lechleiter.

Paul had planned to retire in 2010. With the successful recruitment ofhis successor, he will retire at the end of February 2010.

"Advancing our pipeline to patients as quickly and as safely as possibleis the biggest challenge Lilly faces in 2010 and beyond. We are confidentthat Dr. Lundberg will be able to deliver on this challenge," saidLechleiter.

Lundberg has a Ph.D. from Sweden's world-renowned Karolinska Institute,where he was a professor in the department of pharmacology before moving toindustry. Prior to Karolinska, he attended Gustavus Adolphus College inMinnesota and the University of Gothenburg in Sweden. He has publishedapproximately 500 scientific articles, mainly related to mechanisms of cellsignaling in the nervous, cardiovascular, endocrine and respiratory systems.Lundberg has won a variety of research awards and is a highly cited author inthe areas of biology and biochemistry, pharmacology and neuroscience. He hasbeen a member of the Swedish Medical Research Council and also of theAdvisory Board for Drug Approvals at the Swedish Medical Product Agency. InJanuary 2003, he was appointed Honorary Doctor of Pharmacy at UppsalaUniversity.

During the last 10 years at AstraZeneca, as head of global discoveryresearch, Lundberg was instrumental in delivering more than 150 drugcandidates to the company's pipeline. He had responsibility for discoveryresearch and supported clinical development of potential therapies forcancer, infection, central nervous system disorders, pain, cardiovascular,metabolic and respiratory diseases, gastrointestinal conditions, andinflammation. Lundberg was also responsible for discovery-enablingtechnologies, discovery informatics, drug metabolism and pharmacokinetics,translational science and safety assessment. He has had a leading role inexternal activities, including in-licensing of projects and technologies, aswell as acquisitions of biotech companies. His organization was involved withboth small molecules and biologics. For the past seven years, he has been anexecutive vice president and member of the senior executive team, reportingto the CEO of AstraZeneca.

"I have always had tremendous respect for the quality of people, scienceand products at Lilly. Therefore, I feel honored to be the successor to StevePaul. I'm really looking forward to meeting my colleagues at Lilly andtogether with them conquering the future challenges and advancing innovativemedicines that meet the needs of patients, payers and prescribers," saidLundberg.

According to Paul, "Jan possesses the right mix of scientific expertiseand industry experience needed to advance the innovative pipeline of thiscompany."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growingportfolio of pharmaceutical products by applying the latest research from itsown worldwide laboratories and from collaborations with eminent scientificorganizations. Headquartered in Indianapolis, Ind., Lilly provides answers -through medicines and information - for some of the world's most urgentmedical needs. Additional information about Lilly is available atwww.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

PR Newswire
http://www.prnewswire.com/

Last updated on: 27/08/2010

Advertising